Catalog #CP105
RecombiMAb anti-mouse CXCR2 (CD182)
Clone
Cx2Mab-1-CP105
Reactivities
Mouse
Isotype
Mouse IgG2a, kappa
(switched from Rat IgG2b, kappa)
(switched from Rat IgG2b, kappa)
You may also be interested in:
Product Description
The Cx2Mab-1-CP105 monoclonal antibody is a recombinant, Fc-engineered chimeric version of the original Cx2Mab-1 antibody. The variable domain sequences are identical but the constant region sequences have been switched from Rat IgG2b, κ to Mouse IgG2a, κ for use in murine models. Species-matched chimeric antibodies exhibit regulated effector functions—including Fc receptor binding and complement activation—and result in less immunogenicity and formation of anti-drug antibodies (ADAs) than xenogenic antibodies in animal models. This antibody has an effector function competent Fc domain allowing for activation of Fcγ receptors (FcγRs) to trigger antibody‑dependent cellular cytotoxicity (ADCC), antibody‑dependent cellular phagocytosis (ADCP), complement‑dependent cytotoxicity (CDC) and opsonization to promote target cell depletion. The mouse IgG2a isotype demonstrates strong effector functions due to potent interaction with mFcγRIV, which is functionally similar to the FcγRIIIa receptor involved in human ADCC. The highly controlled sequence and lack of genetic drift in recombinant antibodies provide more reliable and reproducible results over hybridoma derived antibodies.
The Cx2Mab-1 antibody reacts with mouse CXC chemokine receptor 2 (CXCR2), also known as CD182, GRO/MGSA receptor, and IL-8RB. This antibody targets the N-terminal extracellular domain of CXCR2, which is important for ligand binding and receptor activation. CXCR2 is a G protein-coupled receptor (GPCR) that coordinates immune cell trafficking during immune responses. CXCR2 ligands include its primary ligands CXCL8 (IL-8) and CXCL1 (GRO-α) as well as CXCR2, CXCL2, CXCL3, CXCL5, CXCL6, and CXCL7. Leukocytes (particularly neutrophils and monocytes) constitutively express CXCR2, whereas parenchymal cells such as fibroblasts, hepatocytes, and neurons also express this receptor to varying degrees of abundance. CXCR2 and its ligands facilitate various tissue-dependent signals for regulating cellular survival, proliferation, differentiation, adhesion, and migration. In cancer tissues, CXCR2 signaling is critical to the processes of tumor angiogenesis, growth, and chemoresistance, and a high expression of CXCR2 on myeloid cells drives their migration to the tumor cells. Blockade of CXCR2-mediated recruitment of myeloid-derived suppressor cells (MDSCs) into the tumor microenvironment and the pre-metastatic niche is emerging as an attractive approach to boost cancer immunotherapy.
The Cx2Mab-1 antibody reacts with mouse CXC chemokine receptor 2 (CXCR2), also known as CD182, GRO/MGSA receptor, and IL-8RB. This antibody targets the N-terminal extracellular domain of CXCR2, which is important for ligand binding and receptor activation. CXCR2 is a G protein-coupled receptor (GPCR) that coordinates immune cell trafficking during immune responses. CXCR2 ligands include its primary ligands CXCL8 (IL-8) and CXCL1 (GRO-α) as well as CXCR2, CXCL2, CXCL3, CXCL5, CXCL6, and CXCL7. Leukocytes (particularly neutrophils and monocytes) constitutively express CXCR2, whereas parenchymal cells such as fibroblasts, hepatocytes, and neurons also express this receptor to varying degrees of abundance. CXCR2 and its ligands facilitate various tissue-dependent signals for regulating cellular survival, proliferation, differentiation, adhesion, and migration. In cancer tissues, CXCR2 signaling is critical to the processes of tumor angiogenesis, growth, and chemoresistance, and a high expression of CXCR2 on myeloid cells drives their migration to the tumor cells. Blockade of CXCR2-mediated recruitment of myeloid-derived suppressor cells (MDSCs) into the tumor microenvironment and the pre-metastatic niche is emerging as an attractive approach to boost cancer immunotherapy.
Specifications
| Isotype | Mouse IgG2a, κ |
|---|---|
| Recommended Isotype Control(s) | RecombiMAb mouse IgG2a isotype control, unknown specificity |
| Recommended Dilution Buffer | InVivoPure pH 8.0 Dilution Buffer |
| Immunogen | Synthetic peptide corresponding to mouse CXCR2’s N-terminal sequence - MGEFKVDKFNIEDFFSGDL |
| Reported Applications |
Flow cytometry For details on in vivo applications please contact technicalservice@bioxcell.com |
| Formulation |
PBS, pH 8.0 Contains no stabilizers or preservatives |
| Endotoxin |
≤0.5EU/mg (≤0.0005EU/μg) Determined by LAL assay |
| Aggregation* |
<5% Determined by SEC |
| Purity |
≥95% Determined by SDS-PAGE |
| Sterility | 0.2 µm filtration |
| Production | Purified from mammalian cell supernatant in an animal-free facility |
| Molecular Weight | 150 kDa |
| Murine Pathogen Tests |
Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative |
| Storage | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
| Need a Custom Formulation? | See All Antibody Customization Options |
* Additional quality control measures for our InVivoPlusâ„¢ products include advanced binding validation, murine pathogen screening, protein aggregation screening, and ultra-low endotoxin levels. The superior quality of our InVivoPlusâ„¢ products will meet and exceed the strict demands and rigorous standards required for in vivo research. Learn more about the InVivoPlusâ„¢ difference here.